CLOVIS ONCOLOGY (CLVS) Covered Calls

CLOVIS ONCOLOGY covered calls Clovis Oncology Inc is a biopharmaceutical company. The Company is engaged in acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets.

You can sell covered calls on CLOVIS ONCOLOGY to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CLVS (prices last updated Fri 4:16 PM ET):

CLOVIS ONCOLOGY (CLVS) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
26.36 -3.60 26.37 26.55 6.1M - 1.6B
Covered Calls For CLOVIS ONCOLOGY (CLVS)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Nov 16 26 2.75 23.80 9.2% 116%
Jan 18 26 4.50 22.05 17.9% 71.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. The company has three product candidates in its clinical development pipeline: CO-1686, an oral epidermal growth factor receptor (EGFR), covalent inhibitor currently in Phase I/II development for the treatment of non-small cell lung cancer (NSCLC), in patients with initial activating EGFR mutations as well as the T790M primary resistance mutation; rucaparib, an oral, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor currently in Phase II development for ovarian cancer, which includes the global ARIEL2 (Assessment of Rucaparib in Ovarian Cancer Phase 2 Trial) study; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. Clovis Oncology was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.